Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INGN 225

Next Previous
X
Search
Drug Profile

INGN 225

Alternative Names: Ad.p53 DC vaccine; Adenovirus-p53 transduced dendritic cell vaccine; Advexin-based-dendritic-cell-vaccine; Autologous dendritic cell adenovirus p53 vaccine; Dendritic Cell based p53 Vaccine

Latest Information Update: 12 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; Vanderbilt-Ingram Cancer Center
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Lumos Pharma; University of Nebraska Medical Center
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; P53 gene stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Small cell lung cancer

Most Recent Events

  • 31 Jan 2019 H. Lee Moffitt Cancer Center and Research Institute completes a phase II trial in Small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (SC) (NCT00618891) (NCT00617409)
  • 29 Mar 2018 H. Lee Moffitt Cancer Center and Research Institute initiates a phase II trial for Small Cell Lung Cancer (Second-line therapy or greater, Combination therapy) in USA (SC) (NCT03406715)
  • 23 Jan 2018 H. Lee Moffitt Cancer Center and Research Institute plans a phase II trial for Small Cell Lung Cancer (Second-line or greater therapy, Combination therapy) in USA (SC) (NCT03406715)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top